Mursla: Using extracellular vesicles to detect cancer

Mursla believes its extracellular vesicle-based biopsy platform combines the specificity of a tissue biopsy with the simplicity of liquid biopsy. The company aims to market its first product, a liver cancer surveillance laboratory developed test, in the U.S. by the end of 2025. 

Mursla Ltd. is characterizing populations of extracellular vesicles (EVs), membrane-bound structures filled with various biomolecules that are released from nearly all cell types, to identify the origins of the EVs and determine how they can be used to detect specific diseases. ...